ModifiedPremera BluecrossPolicy N/A

Deep Brain Stimulation (DBS) — Coverage Criteria

Defines medical necessity, investigational uses, documentation, and coding for deep brain stimulation for movement disorders and selected psychiatric indications; intended for providers requesting coverage from Premera Bluecross.

Policy Summary

PayerPremera Bluecross

PolicyDeep Brain Stimulation (DBS) — Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial updates to OCD coverage stancedevice and coding updates

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization documenting that medical necessity criteria and required documentation are met for the specific DBS target (including OCD-specific documentation when applicable).

SourceLink

POLICY UPDATE CHANGES

Recent 2026 updates summarize accumulating evidence supporting DBS for treatment-resistant obsessive-compulsive disorder (OCD) including multiple trials and meta-analyses reporting substantial Y-BOCS score reductions and responder rates.

Updated FDA regulatory approvals and device table expanded to include systems and indications through 2025 (and BrainSense adaptive DBS noted with 2025/2026 reference).

Changed the status of deep brain stimulation (DBS) for treatment-resistant Obsessive-compulsive disorder (OCD) from investigational to medically necessary when specified criteria are met.

Added investigational policy statement for adaptive deep brain stimulation in Parkinson disease.

Added contraindication that use of DBS in conjunction with transcranial magnetic stimulation (TMS) or any other neuromodulation modality is not medically necessary.

Added HCPCS code C1820 and removed HCPCS code C1607 (moved to another policy); also earlier added C1607 in 2026 coding update then removed in 2026 March update.

multiple

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Medical Necessity

DBS of the thalamus

Covered when ANY of the following are met:

Thalamic DBS for tremor: Unilateral treatment of disabling, medically unresponsive tremor due to Parkinson disease OR essential tremor; OR bilateral treatment of disabling, medically unresponsive tremor in both upper limbs due to Parkinson disease OR essential tremor.See definition of disabling, medically unresponsive tremor

Disabling, medically unresponsive tremor is defined as tremor causing significant limitation in daily activities and inadequately controlled by maximal medication dosage for at least three months before implant.

DBS of globus pallidus or subthalamic nucleus

Covered when ALL of the following are met for Parkinson disease OR for primary dystonia:

Parkinson disease (GPi or STN): Unilateral or bilateral DBS of the globus pallidus internus (GPi) or subthalamic nucleus (STN) when ALL are met: a good response to levodopa; AND motor complications not controlled by drug treatment; AND one of: UPDRS motor score >=30 when off medications (~12 hours) OR Parkinson disease duration >=4 years.UPDRS motor >=30 or PD duration >=4 years

Primary dystonia (GPi or STN): Unilateral or bilateral DBS of GPi or STN for individuals older than 7 years with chronic, intractable (drug-refractory) primary dystonia (may include generalized, segmental, hemidystonia, and cervical dystonia).Age >7 years

Bilateral DBS of the striatum for OCD

Covered when ALL of the following are met:

Age and severity: Individual is aged 18 years or older AND is experiencing moderate to severe obsessive-compulsive disorder symptoms documented by clinician assessment or a standardized severity scale.Age >=18

Prior treatment failures: Failure of 3 or more medications (including clomipramine and SSRIs) AND failure of a course of Exposure and Response Prevention (ERP) therapy.>=3 medication failures

Each failed medication must be individually identified with reason for failure; unless stopped for intolerable adverse effects, a medication trial requires at least 30 continuous days without adequate improvement.

TMS requirement or exemption: Symptoms remained moderate/severe after a course of transcranial magnetic stimulation (TMS), OR TMS was stopped due to intolerable/incapacitating/dangerous side effects, OR there is a contraindication to TMS, OR legitimate factors make a full TMS regimen a hardship (note: concern about side effects or patient preference alone are not valid contraindications).

Indication-specific coverage conclusions

Coverage stance varies by condition based on available evidence:

Primary dystonia: For primary dystonia, systematic reviews, RCTs, and case series (including a pooled analysis of mainly uncontrolled studies and two double-blind RCTs) demonstrate improvement in motor and disability scores; DBS is judged to improve net health outcome.

Adaptive DBS for Parkinson disease: Adaptive deep brain stimulation (aDBS) for Parkinson disease has limited evidence including one RCT showing feasibility but substantial device-related and serious adverse events; current evidence is insufficient to conclude net health benefit.

Epilepsy: For epilepsy, two RCTs and multiple observational studies reported mixed seizure frequency results and substantial adverse events; evidence is insufficient to determine net health benefit.

Tourette syndrome: For Tourette syndrome, available RCTs produced inconsistent results with high rates of serious adverse events; evidence is insufficient to determine net health benefit.

Medicare-covered DBS indications (VIM for tremor; STN/GPi for PD)

Covered when ALL of the following are met for the specified target:

Thalamic VIM DBS for essential tremor or tremor-dominant PD: Diagnosis of essential tremor (postural or kinetic hand tremors without other neurologic signs) OR idiopathic Parkinson disease of tremor-dominant form; marked disabling tremor level 3 or 4 on Fahn-Tolosa-Marin Clinical Tremor Rating Scale (or equivalent) in the extremity intended for treatment causing significant limitation in daily activities despite optimal medical therapy; willingness and ability to cooperate during conscious operative procedure and post-surgical follow-up and stimulator/medication adjustments; use of FDA-approved devices or devices used per FDA/IDE Category B protocols.severity level 3 or 4

Medicare national coverage conditions

STN or GPi DBS for Parkinson disease: Diagnosis of Parkinson disease with at least 2 cardinal features (tremor, rigidity, bradykinesia); advanced idiopathic PD per Hoehn & Yahr stage or UPDRS III motor subscale; L-dopa responsive with clearly defined 'on' periods; persistent disabling Parkinson symptoms or drug side effects despite optimal medical therapy; willingness and ability to cooperate during conscious operative procedure and post-surgical evaluations and stimulator adjustments; use of FDA-approved devices or IDE Category B protocols.clinical staging or UPDRS criteria

Restricted / research-only indications

Use is limited or recommended only in research/special arrangements for the following:

Refractory chronic pain (excluding headache): Evidence indicates DBS may be efficacious in some patients but is associated with serious risks; use should be limited to select refractory cases with full informed consent regarding incomplete symptom control and rare risk of death (per NICE guidance).N/A

NICE 2011 guidance

Intractable trigeminal autonomic cephalalgias (e.g., cluster headache): Evidence is limited and inconsistent with known serious adverse effects; use restricted per NICE guidance.N/A

NICE 2011 guidance

Refractory epilepsy (anterior thalamic targets): Evidence on efficacy and safety is limited in quantity and quality; procedure should only be used with special arrangements for governance, consent, audit, or in research; other epilepsy targets only in research.

Treatment-resistant OCD

Consider DBS for treatment-resistant OCD when ALL of the following are met:

OCD candidate criteria: Severe, treatment-resistant obsessive-compulsive disorder with documented failure of evidence-based therapies including multiple SSRIs, clomipramine, and Exposure and Response Prevention (ERP); no other viable treatment options; patient selection appropriate for bilateral striatal targets (e.g., anterior limb of internal capsule, bed nucleus of the stria terminalis, nucleus accumbens).failure of multiple standard therapies

2026 evidence summaries report pooled mean ~47% reduction in Y-BOCS and ~66% full responders in meta-analysis; each failed medication must be documented with reason for failure and required durations per policy.

Updated coverage stances

Policy status changes and investigational positions

DBS for OCD: Deep brain stimulation for treatment-resistant obsessive-compulsive disorder is designated medically necessary when specified criteria and documentation are met.see policy criteria

Criteria details, contraindications, and documentation requirements were added in the March 1, 2026 update.

Adaptive DBS in Parkinson disease: Adaptive deep brain stimulation for Parkinson disease is investigational (not medically necessary).N/A

Investigational statement added in 2025 review; cited RCT evidence is insufficient to demonstrate net health benefit.

Use of deep brain stimulation (DBS) in combination with transcranial magnetic stimulation (TMS) or any other neuromodulation modality for the treatment of obsessive-compulsive disorder or any psychiatric or substance-use disorder is considered not medically necessary. This includes situations where modalities would be used concurrently or as an integrated neuromodulation strategy; if a DBS device has been deactivated, a regular course of TMS may be considered separately only if TMS criteria are otherwise met.

This policy change was recorded in the March 1, 2026 update and is an operational exclusion that should be verified during prior authorization and clinical review; concurrent or combined neuromodulation approaches are a basis for denial of coverage per the policy.

Deep brain stimulation is considered investigational for a number of other disorders beyond the covered movement-disorder and selected psychiatric indications. Examples explicitly listed include post-traumatic dyskinesia, tardive dyskinesia, and chronic cluster headaches, as well as multiple psychiatric or neurologic diagnoses such as alcohol addiction, Alzheimer disease, anorexia nervosa, chronic pain, depression, epilepsy, and multiple sclerosis tremor.

Because randomized controlled trial evidence is limited or absent for many of these conditions, DBS for these indications remains investigational and is not supported as medically necessary outside of approved research or special arrangements. The policy history documents this investigational stance and related coding/coverage updates.

Several conditions are noted to have only case series or otherwise limited evidence supporting DBS. These include anorexia nervosa, alcohol addiction, Alzheimer disease, Huntington's disease, and some chronic pain indications. The policy states that randomized controlled trials are needed to evaluate efficacy for these disorders and the current evidence is insufficient to determine a net health benefit.

For these indications, DBS is considered investigational and coverage is not supported outside of clinical trials or research contexts until higher-quality evidence becomes available.

DBS is not covered for certain clinical scenarios that would preclude expected benefit or pose unacceptable risk. These exclusions include non-idiopathic Parkinson's disease and Parkinson-plus syndromes; cognitive impairment, dementia, or depression that would interfere with benefit; current psychosis or active substance (alcohol or drug) abuse; structural lesions (for example, basal ganglia stroke, tumor, or vascular malformation) causing the movement disorder; prior movement-disorder surgery within the affected basal ganglion; and significant medical, surgical, neurologic, or orthopedic comorbidities that contraindicate DBS surgery or stimulation.

Additional contraindications specific to obsessive-compulsive disorder (OCD) were added in the 2026 update and must be assessed during eligibility evaluation and prior authorization; such contraindications are grounds for deeming DBS not medically necessary.

Restating the exclusion: the policy explicitly considers the use of DBS in conjunction with TMS or any other neuromodulation modality to be not medically necessary. This operational exclusion is intended to prevent concurrent multimodal neuromodulation strategies for OCD or other psychiatric/substance-use disorders and should be applied in coverage determinations.

If a previously implanted DBS device is deactivated, subsequent standard TMS may be considered only if the individual otherwise meets medical necessity criteria for TMS.

Deep brain stimulation for obsessive-compulsive disorder is contraindicated and therefore considered not medically necessary when certain psychiatric or procedural contraindications are present. Contraindications added in the 2026 update include current psychotic or manic symptoms, planned full-body MRI, and planned therapeutic diathermy (short-wave, microwave, therapeutic ultrasound) or surgical diathermy at any body location. These contraindications should be documented during prior authorization review.

Providers must confirm the absence of these contraindications before approving DBS for treatment-resistant OCD, as their presence precludes coverage under this policy.

For indications where randomized trials have not demonstrated consistent benefit or where evidence is insufficient—such as adaptive (aDBS) systems in Parkinson disease—the policy concludes that available data do not support routine clinical use. The summary of evidence for aDBS reports one RCT with feasibility outcomes and substantial device-related adverse events, and the policy therefore treats these approaches as investigational or not medically necessary.

Operationally, technologies and targets lacking consistent RCT-demonstrated benefit should be considered investigational in coverage decisions until further high-quality evidence establishes improved net health outcomes.

There are evidence gaps and safety concerns for some chronic pain and epilepsy DBS targets. NICE guidance (2011, 2020) and the policy summary note that DBS for refractory chronic pain (excluding headache) and for certain trigeminal autonomic cephalalgias has limited and inconsistent evidence and is associated with serious risks; use is recommended only in select refractory cases or with special arrangements. For epilepsy, two RCTs (including one with N=110) reported mixed efficacy and substantial adverse events (>30% in one trial), and the evidence is judged insufficient to determine net health benefit for many epilepsy targets.

Consequently, coverage for these indications is restricted or limited to research or special-arrangement contexts pending stronger evidence on efficacy and safety.

Adaptive deep brain stimulation (aDBS) for Parkinson disease is explicitly listed as investigational in this policy. The evidence review identified one randomized controlled trial reporting feasibility outcomes and high rates of device-related and serious adverse events, and the policy considers the evidence insufficient to conclude a net health benefit for aDBS.

As a result, aDBS should not be approved as medically necessary outside of clinical studies or formal research protocols until additional robust efficacy and safety data are available.

Coding and Billing

Covered CPT CodesCPTCovered

61850	Twist drill or burr hole(s) for implantation of neurostimulator or electrodes, cortical.
61860	Craniectomy or craniotomy for implantation of neurostimulator electrodes, cerebral, cortical.
61863	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, ...
61864	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), without use of intraoperative microelectrode recording; each additional array.
61867	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; first array.
61868	Twist drill, burr hole, craniotomy, or craniectomy with stereotactic implantation of neurostimulator electrode array in subcortical site (e.g., thalamus, globus pallidus, subthalamic nucleus, periventricular, periaqueductal gray), with use of intraoperative microelectrode recording; each additional array.
61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to a single electrode array.
61886	Insertion or replacement of cranial neurostimulator pulse generator or receiver; with connection to 2 or more electrode arrays.

Covered HCPCS / Device CodesHCPCSCovered

C1767	Generator, neurostimulator (implantable), nonrechargeable.
C1778	Lead, neurostimulator (implantable).
C1820	Generator, neurostimulator (implantable), with rechargeable battery and charging system.
L8680	Implantable neurostimulator electrode, each.
L8685	Implantable neurostimulator pulse generator, single array, rechargeable, includes extension.
L8686	Implantable neurostimulator pulse generator, single array non-rechargeable, includes extension.
L8687	Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension.
L8688	Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension.

Regulatory product/PMA/HDE and FDA product codes mentionedmixed

P96009	Activa Deep Brain Stimulation Therapy System (PMA/HDE base code referenced).
H050003	Reclaim DBS Therapy for Obsessive Compulsive Disorder (HDE).
P140009	Brio/Infinity DBS system PMA reference.
P150031	Vercise DBS System PMA reference.
MHY	Percept PC Deep Brain Stimulation FDA product code.
MBX	Activa Deep Brain Stimulation Therapy System FDA product code variant.

HCPCS coding updatesHCPCS

C1820	Added HCPCS code C1820.
C1607	HCPCS code C1607 was added Jan 1, 2026 then removed (moved to policy 10.01.533).
C1767	Previously added HCPCS code C1767.
C1778	Previously added HCPCS code C1778.

inv-22: Failed medication trial duration

Failed medication trial duration>= 3 months at maximal tolerated dose

Minimum days per medication trialUnless stopped for intolerable adverse effects, a medication trial requires at least 30 continuous days without adequate improvement to be considered failed

Documentation requirement for failed medicationsEach failed medication must be individually identified with reason(s) for failure

inv-23: Tremor severity (Fahn-Tolosa-Marin Clinical Tremor Rating Scale)

Tremor severity thresholdLevel 3 or 4 on the Fahn‑Tolosa‑Marin Clinical Tremor Rating Scale in the extremity intended for treatment

Prior Authorization, Documentation, and Operational Actions

Prior Authorization

Prior Authorization Required for DBS Implantation and Device Codes

Prior authorization is required for all deep brain stimulation (DBS) surgical implantation and device-related services. Prior authorization requests must identify the specific DBS target (thalamus, globus pallidus, subthalamic nucleus, or striatum) and include documentation of medical necessity for that target and planned laterality (unilateral or bilateral).

Applies to surgical implantation and device codes (including current HCPCS/CPT codes for DBS implantation and generator/device supplies).
Include planned target area in the request (thalamus/VIM, GPi, STN, striatum/ALIC/BNST).

Prior Authorization

Prior Authorization: FDA‑Approved Device and Medicare Clinical Criteria

Prior authorization must verify use of an FDA-approved device when Medicare coverage criteria apply and document that the clinical presentation meets applicable Medicare or payer-specific criteria (e.g., diagnosis, severity scales, responsiveness to therapy). Requests for non‑FDA–approved or off‑label device use should include trial identifiers if the implant occurs in the context of a clinical study.

Document device model and FDA approval status in the submission.

Background and Scope

Deep brain stimulation is a stereotactic neurosurgical procedure that places implanted electrodes into specific deep brain nuclei (commonly the thalamus, globus pallidus internus GPi, subthalamic nucleus STN, or striatum including anterior limb of internal capsule/bed nucleus of the stria terminalis/nucleus accumbens) and connects them to an implanted pulse generator. The intent is to modulate abnormal neural circuits to reduce symptoms in movement disorders (for example, essential tremor, Parkinson disease, primary dystonia) and selected psychiatric disorders.

Typical targets vary by indication: thalamic (ventral intermediate nucleus, VIM) stimulation is used for disabling tremor; GPi or STN stimulation is used for Parkinson disease and dystonia; bilateral striatal targets are used for treatment-resistant obsessive-compulsive disorder. DBS is an alternative to lesioning procedures and requires patient ability to cooperate with the operative and follow-up process.

Definitions and Clinical Terms

inv-42: Disabling, medically unresponsive tremor

DefinitionDisabling, medically unresponsive tremor is tremor causing significant limitation in daily activities and inadequately controlled by maximal medication dose for at least 3 months before implant

Functional impactMust produce significant limitation in activities of daily living despite optimal medical therapy

Medication optimizationInadequate control must be documented after maximal tolerated medication dosing for the required duration

inv-43: Striatum (anatomy and OCD targets)

Striatum componentsIncludes caudate nucleus, internal capsule, putamen, and nucleus accumbens

Typical OCD DBS targetsCommon bilateral targets for OCD include the anterior limb of the internal capsule and the bed nucleus of the stria terminalis (within the striatum)

References, Evidence Summary, and Revision History

This policy references multiple professional society guidance documents and health-technology assessments that inform coverage positions, including the American Academy of Neurology (AAN), the Congress of Neurological Surgeons (endorsed by the AAN), the American Society for Stereotactic and Functional Neurosurgery, and multiple United Kingdom NICE guidance documents addressing tremor, dystonia, chronic pain, cluster headache, and epilepsy. These sources are cited in the evidence review and support differential recommendations by indication.

Regulatory summaries and device approvals from the U.S. Food and Drug Administration (FDA) and updated literature reviews through 2025–2026 are also incorporated into the policy’s evidence assessment and the documented policy status changes.

The policy cites a broad set of references supporting its evidence summaries and updates; the reference list includes articles, systematic reviews, randomized controlled trials, meta-analyses, and regulatory documents spanning references numbered approximately 14 through 94 in the policy bibliography. These references underpin the condition-specific evidence statements and the 2026 update that revised DBS for OCD to medically necessary when criteria are met.

Selected recent additions and key citations (for example, systematic reviews and device SSEDs) are included in the references and were added in the 2025–2026 history entries that accompanied the policy revisions.

2026-03-01

Policy Summary

PayerPremera Bluecross

PolicyDeep Brain Stimulation (DBS) — Coverage Criteria

Policy CodePolicy N/A

Change TypeMaterial updates to OCD coverage stancedevice and coding updates

Effective DateN/A

Next Review DateN/A

Key ActionSubmit prior authorization documenting that medical necessity criteria and required documentation are met for the specific DBS target (including OCD-specific documentation when applicable).

SourceLink

On This Page

Denial Risk

Contraindications That May Preclude Coverage

Contraindications may preclude coverage. Individuals who are poor surgical candidates or who have conditions that would prevent benefit or safe use of DBS should be identified and may be denied coverage.

Unstable medical problems or significant co-morbidities that make the individual a poor surgical risk.
Need for repeated full‑body MRIs after implantation.
Dementia or cognitive impairment that would interfere with cooperation and follow-up.
Recent (<6 months) botulinum toxin injections where specified as a contraindication.
Presence of implanted devices (e.g., certain cardiac pacemakers) that preclude safe stimulation.

Denial Risk

Safety Concerns and Insufficient Benefit Risk Denial

Safety signals and insufficient benefit in the evidence base may lead to denial for some indications. Submit complete adverse event history and prior-device experience; the reviewer will consider trial and long‑term safety data when evaluating medical necessity.

Randomized trials and long-term follow-up have reported substantial adverse events and serious device‑related complications in some indications (e.g., epilepsy, Tourette syndrome).
For investigational indications or where net health benefit is uncertain, requests may be denied. Provide longitudinal follow-up data when available to support benefit and tolerability.

Prior Authorization

Medicare Coverage Exclusion Triggers and Documentation

Medicare coverage exclusions and requirements must be addressed in the prior authorization. If Medicare national coverage rules apply, the request must document that the patient meets all device‑specific, diagnostic, and severity criteria, and that none of the Medicare exclusions are present.

Devices must be FDA‑approved for DBS or used under an FDA‑approved IDE protocol.
For thalamic (VIM) DBS and STN/GPi DBS in Parkinson disease, document required diagnostic features, severity scale scores (e.g., Fahn‑Tolosa‑Marin tremor rating or UPDRS Part III), L‑dopa responsiveness where required, and willingness/ability to cooperate.
Exclude non‑idiopathic Parkinsonism, cognitive impairment/dementia interfering with benefit, current psychosis/substance abuse, or other listed Medicare exclusions.

Documentation Required

Trial Identifiers and Enrollment

If DBS implantation occurs in the context of an ongoing clinical trial or post‑approval study, include trial identifiers and enrollment details. Trial identifiers can support investigational or limited‑coverage cases when applicable.

Include NCT number, IDE/protocol ID, trial name, and current enrollment status.
Indicate whether implantation is part of a commercial, post‑approval, or investigational protocol and provide the trial consent and approvals if requested.

Prior Authorization

DBS for OCD — Prior Authorization and Required Documentation

When requesting coverage for DBS for treatment‑resistant OCD, prior authorization must include specific documentation demonstrating that all OCD‑specific eligibility criteria are met and that required prior treatments failed or were not tolerated.

Age ≥18 years and documentation of moderate to severe OCD (e.g., baseline Y‑BOCS score and clinical history).
Planned bilateral striatal target (specify ALIC, BNST, nucleus accumbens, or other striatal target).
Documentation of failure of 3 or more medications (identify each medication, dose, duration, and reason for failure).
Documentation of adequate trial of Exposure and Response Prevention (ERP) therapy and outcomes.
Documentation that TMS was tried with insufficient benefit or could not be completed due to intolerance/contraindication, or justification for inability to receive TMS (hardship documentation).

Prior Authorization

Medication Failure and Clinical Criteria Required for DBS in Refractory Epilepsy

For refractory epilepsy, prior authorization must document prior medication failures and epilepsy‑specific eligibility criteria before DBS will be considered medically necessary.

Evidence of failure of two or more appropriately dosed antiseizure medications (each drug identified with dose, duration, and reason for failure).
Documentation that seizures are focal onset (with or without generalization) and that the seizure focus is not amenable to resection or resection has failed.
Supportive diagnostic testing (EEG, MRI, or other localization studies) as applicable to demonstrate focal onset or nonresectable focus.

inv-45: FDA-approved device indications

Medtronic ActivaActiva Deep Brain Stimulation Therapy System (Medtronic) — PMA P96009; indications include stimulation of GPi or STN for PD and primary dystonia

Medtronic ReclaimReclaim DBS Therapy for OCD (Medtronic) — HDE H050003; indication: bilateral stimulation of the anterior limb of the internal capsule for severe OCD

Boston Scientific Vercise/Vercise GenusVercise systems (Boston Scientific) — PMA references P150031 and related supplements; indications include STN/GPi stimulation for PD

Other systemsBrio/Infinity (St. Jude/Abbott) and Percept PC and SenSight (Medtronic) are listed with device-specific PMA/HDE or FDA product codes and indications